<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Health Serv Res</journal-id><journal-id journal-id-type="iso-abbrev">BMC Health Serv Res</journal-id><journal-title-group><journal-title>BMC Health Services Research</journal-title></journal-title-group><issn pub-type="epub">1472-6963</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24674307</article-id><article-id pub-id-type="pmc">3978079</article-id><article-id pub-id-type="publisher-id">1472-6963-14-137</article-id><article-id pub-id-type="doi">10.1186/1472-6963-14-137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A prospective analysis of false positive events in a National Colon Cancer Surveillance Program</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Augestad</surname><given-names>Knut Magne</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I3">3</xref><email>knut.magne.augestad@telemed.no</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Norum</surname><given-names>Jan</given-names></name><xref ref-type="aff" rid="I4">4</xref><xref ref-type="aff" rid="I5">5</xref><email>Jan.Norum@helse-nord.no</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Rose</surname><given-names>Johnie</given-names></name><xref ref-type="aff" rid="I6">6</xref><xref ref-type="aff" rid="I7">7</xref><email>Johnie.Rose@case.edu</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Lindsetmo</surname><given-names>Rolv-Ole</given-names></name><xref ref-type="aff" rid="I3">3</xref><xref ref-type="aff" rid="I5">5</xref><email>Rolv-Ole.Lindsetmo@unn.no</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Surgery, Division of Colorectal Surgery, University Hospitals Case Medical Center, Cleveland, OH, USA</aff><aff id="I2"><label>2</label>Norwegian Center of Integrated Care and Telemedicine, University Hospital of North Norway, Troms&#x000f8;, Norway</aff><aff id="I3"><label>3</label>Department of Gastrointestinal Surgery, University Hospital of North Norway, Troms&#x000f8;, Norway</aff><aff id="I4"><label>4</label>Northern Norway Regional Health Authority Trust, Bod&#x000f8;, Norway</aff><aff id="I5"><label>5</label>Institute of Clinical Medicine, Faculty of Health Sciences, University of Troms&#x000f8; &#x02013; The Artic University of Norway, Troms&#x000f8;, Norway</aff><aff id="I6"><label>6</label>Department of Family Medicine and Community Health, Case Western Reserve University School of Medicine, Cleveland, OH, USA</aff><aff id="I7"><label>7</label>Case Comprehensive Cancer Center, Cleveland, OH, USA</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>27</day><month>3</month><year>2014</year></pub-date><volume>14</volume><fpage>137</fpage><lpage>137</lpage><history><date date-type="received"><day>6</day><month>11</month><year>2013</year></date><date date-type="accepted"><day>25</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Augestad et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Augestad et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1472-6963/14/137"/><abstract><sec><title>Background</title><p>The survival benefits of colon cancer surveillance programs are well delineated, but less is known about the magnitude of false positive testing. The objective of this study was to estimate the false positive rate and positive predictive value of testing as part of a surveillance program based on national guidelines, and to estimate the degree of testing and resource use needed to identify a curable recurrence.</p></sec><sec><title>Methods</title><p>Analysis of clinically significant events leading to suspicion of cancer recurrence, false positive events, true cancer recurrences, time to confirmation of diagnosis, and resource use (radiology, blood samples, colonoscopies, consultations) among patients included in a randomised colon cancer surveillance trial.</p></sec><sec><title>Results</title><p>110 patients surgically treated for colon cancer were followed according to national guidelines for 1884 surveillance months. 1105 tests (503 blood samples, 278 chest x-rays, 209 liver ultrasounds, 115 colonoscopies) and 1186 health care consultations were performed. Of the 48 events leading to suspicion of cancer recurrence, 34 (71%) represented false positives. Thirty-one (65%) were initiated by new symptoms, and 17 (35%) were initiated by test results. Fourteen patients had true cancer recurrence; 7 resections of recurrent disease were performed, 4 of which were successful R0 metastasis Resections. 276 tests and 296 healthcare consultations were needed per R0 resection; the cost per R0 surgery was &#x000a3; 103207. There was a 29% probability (positive predictive value) of recurrent cancer when a diagnostic work-up was initiated based on surveillance testing or patient complaints.</p></sec><sec><title>Conclusion</title><p>We observed a high false positive rate and low positive predictive value for significant clinical events suggestive of possible colorectal cancer relapse in the setting of a post-treatment surveillance program based on national guidelines. Providers and their patients should have an appreciation for the modest positive predictive value inherent in colorectal cancer surveillance programs in order to make informed choices, which maximize quality of life during survivorship. Better means of tailoring surveillance programs based on patient risk would likely lead to more effective and cost-effective post-treatment follow-up.</p></sec><sec><title>Trial registration</title><p>ClinicalTrials.gov identifier <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/NCT00572143">NCT00572143</ext-link>. Date of trial registration: 11<sup>th</sup> of December 2007.</p></sec></abstract><kwd-group><kwd>Colorectal cancer</kwd><kwd>Surveillance</kwd><kwd>Follow-up</kwd><kwd>False positive test</kwd><kwd>Positive predictive value</kwd><kwd>Metastases resection</kwd><kwd>Cost-effectiveness</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Colon cancer is the third most common cancer in the western world, and surgery is the only curative treatment. Approximately one-third of those resected will experience recurrent disease with an expected survival of less than two years [<xref ref-type="bibr" rid="B1">1</xref>]. Most patients treated with curative intent are included in some form of surveillance program involving periodic evaluations to detect asymptomatic recurrence. Reviews comparing various surveillance programs have suggested that more intensive surveillance strategies tend to increase five-year overall survival by 5-10% [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>However, all preventive programs have associated costs and risks [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. The survival benefits of a surveillance program for colon cancer survivors are well known, but much less is known about the potential negative impacts for patients and their loved ones [<xref ref-type="bibr" rid="B3">3</xref>]. False positive test results may negatively impact quality of life (QoL) by leading patients and family members to believe that recurrence has occurred. On the other hand, false negative tests may result in diagnostic delay during which a potentially curable recurrent cancer may become inoperable. In order to more rationally weigh benefits and harms of post-operative surveillance programs, patients and providers need information to help them better understand the implications of positive and negative test results [<xref ref-type="bibr" rid="B6">6</xref>]. In addition, it is important to understand the resource use associated with work-up of suspected recurrence and the benefit which can be expected in terms of opportunities for curative treatment of recurrence.</p><p>Previously, we have reported the cost-effectiveness and QoL results from a Norwegian randomized trial comparing general practitioner (GP) versus surgeon-organised colon cancer surveillance according to national guidelines [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. In this work, we focus on the outcomes of individuals who underwent a diagnostic work-up in response to a positive surveillance test result or development of interval symptoms that raised concern for recurrence. These outcomes include whether the initial positive test results or symptoms represented a false positive or whether they served as the first sign of a true recurrence, as well as subsequent resource use for both true and false positives. Among patients with true positive tests or symptoms, we examine the extent to which curative resection of recurrent disease was possible.</p></sec><sec sec-type="methods"><title>Methods</title><p>Data from a randomised trial assessing a colon cancer surveillance program based on Norwegian National Guidelines (ClinicalTrials.gov identifier NCT00572143), was linked to follow-up data from the electronic medical records (EMRs) of four Norwegian hospitals [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>]. Patients who underwent a diagnostic work-up as a result of a positive surveillance test or symptoms suggesting possible recurrence were identified, and subsequent health care resource utilization was quantified. Patients were enrolled in the surveillance program between June 1, 2007 and December 15, 2011.</p><sec><title>Outcomes</title><p>Primary outcomes included 1) Positive predictive value and false positive rates for initial positive surveillance test results or symptoms suggestive of possible recurrence, 2) subsequent resource use for patients with both true and false positives, and 3) whether curative resection of recurrent disease was possible. Secondary outcomes included time from initial detection to confirmation of recurrence, number needed to test per curative resection of recurrence, and cost per curative resection of recurrence.</p></sec><sec><title>Ethics</title><p>The Regional Committee for Medical Research Ethics (P REK NORD 79/ 2006) and the Norwegian Data Inspectorate approved the research protocol; all patients provided informed written consent.</p></sec><sec><title>Inclusion and exclusion criteria</title><p>Inclusion criteria were age less than 75&#x000a0;years with recent curative surgery for Dukes&#x02019; stage A, B or C colon cancer. Patients receiving postsurgical adjuvant chemotherapy (some Dukes&#x02019; B and all Dukes&#x02019; C) were eligible to participate. Exclusion criteria were age greater than 75&#x000a0;years, membership in a healthcare trust not participating in the trial, inability to provide informed consent, and Dukes&#x02019; stage D cancer. Patients were followed for up to 2&#x000a0;years (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Norwegian Gastrointestinal Cancer Group (NGICG) 2007 Surveillance Program</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Examination/test</bold><hr/></th><th colspan="15" align="center" valign="bottom"><bold>Surveillance cycle (postoperative months)</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center"><bold>1</bold></th><th align="center"><bold>3</bold></th><th align="center"><bold>6</bold></th><th align="center"><bold>9</bold></th><th align="center"><bold>12</bold></th><th align="center"><bold>15</bold></th><th align="center"><bold>18</bold></th><th align="center"><bold>21</bold></th><th align="center"><bold>24</bold></th><th align="center"><bold>30</bold></th><th align="center"><bold>36</bold></th><th align="center"><bold>42</bold></th><th align="center"><bold>48</bold></th><th align="center"><bold>54</bold></th><th align="center"><bold>60</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Chest x-ray<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td></tr><tr><td align="left" valign="bottom">Liver ultrasonography<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td></tr><tr><td align="left" valign="bottom">Colonoscopy<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">CEA measurement<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td><td align="center" valign="bottom">X<hr/></td></tr><tr><td align="left">Clinical examination</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td><td align="center">X</td></tr></tbody></table></table-wrap></sec><sec><title>Description of the surveillance program</title><p>The GP- and surgeon-followed arms underwent the same surveillance regimens based on Norwegian Gastrointestinal Cancer Group 2007 surveillance guidelines (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). The surveillance period included in analyses included nine surveillance cycles (one month through 24&#x000a0;months postoperatively) with regular clinical examinations, CEA measurement, chest x-ray, contrast-enhanced liver ultrasound and colonoscopy according to the intervals described in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>.</p></sec><sec><title>Hospitals, primary and secondary care professionals</title><p>Three local hospitals and one university hospital trust participated. Approximately 100 patients with colon cancer are surgically treated annually at these four hospitals. Approximately 550 GPs work in the health care trust.</p></sec><sec><title>Serious clinical events</title><p>A serious clinical event (SCE) was defined as an episode leading to suspicion of cancer recurrence. An SCE could be triggered by the reported symptoms (at routine consultation or in the intervals between surveillance visits), the clinical findings at surveillance visits or the findings of surveillance tests. The symptoms and clinical findings initiating a diagnostic check-up could include the following: lesion suspicious for colorectal cancer at colonoscopy or rectal examination; increased carcinoembryonic antigen (CEA) values revealed by repeated measurements; blood in the stool detected by the Hemofec (fecal occult blood) test; unexplained abdominal pain; unexplained weight loss of 5&#x000a0;kg during the previous three months; palpable lymphadenopathy; possible metastatic lesions on chest x-ray, liver ultrasound or CT scan; or other signs or symptoms suggestive of cancer recurrence. The time to recurrent cancer diagnosis was defined as the time from an SCE (dated in the GP referral or hospital electronic medical record [EMR]) until the completion of the ensuing diagnostic work-up.</p></sec><sec><title>Data collection</title><p>Data on radiology tests, colonoscopies, blood tests, surgical consultations, surgeries, pathology studies, admissions, and hospital discharges were abstracted from the EMRs of all included patients and were used to identify SCEs. In the case of missing information, the surgeons, GPs, or patients were interviewed by telephone. False positive SCEs were considered to have occurred when an SCE triggered a subsequent diagnostic work-up that ruled out recurrence. We identified successful R0 resections of recurrent local or metastatic disease by examining the surgical and postoperative pathology reports.</p></sec><sec><title>Statistics</title><p>Proportions were compared using 2x2 contingency tables, and Chi Squared or Fisher&#x02019;s exact tests with an alpha level of 0.05. Continuous values were compared using t-tests with a two-sided alpha value of 0.05. The results were expressed using the mean differences for continuous outcomes with the corresponding standard deviations (SD), 95% confidence intervals (CI), and associated p-values. P-values were reported to three decimal places, and p-values less than 0.001 were reported as p&#x02009;&#x0003c;&#x02009;0.001. The surveillance program&#x02019;s positive predictive value was defined as the proportion of SCEs that were true positives (i.e., true cancer recurrences).</p><p>The economic evaluation of cost per R0 resection was performed from a societal perspective. Cost elements were converted into British pounds (BP &#x000a3;) at a rate of BP &#x000a3;&#x02009;=&#x02009;9.39 Norwegian krone (NOK) (<ext-link ext-link-type="uri" xlink:href="http://www.norges-bank.no">http://www.norges-bank.no</ext-link>). Unit costs assigned to health care resources have been previously reported [<xref ref-type="bibr" rid="B8">8</xref>]. To address the uncertainty aspect of the cost per R0 metastases resections, we performed a many-inputs/one-output sensitivity analyses, with results expressed in a Tornado chart. All analyses were performed using IBM SPSS Statistics v 19.0 (IBM Company SPSS 2010) and Microsoft Excel for Mac 2011.</p></sec></sec><sec sec-type="results"><title>Results</title><p>A total of 110 patients surgically treated for colon cancer met the inclusion criteria and were enrolled in the randomised trial. Fifty-five were followed by their GPs and 55 were followed in a surgical outpatient department. Overall, 85 patients (75%; GP 41 vs. surgeon 44) were followed for at least 12&#x000a0;months, and 58 patients (52%; GP 29 vs. surgeon 29) were followed for 24&#x000a0;months. The total surveillance time was 1884 person-months; median follow up time was 17&#x000a0;months. Overall, 1105 tests (colonoscopy n&#x02009;=&#x02009;115, liver ultrasound n&#x02009;=&#x02009;209, chest x-ray n&#x02009;=&#x02009;278, carcinoembryonic antigen n&#x02009;=&#x02009;503) were performed and 1186 consultations occurred (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Demographics of the patients enrolled in a National CRC Surveillance Program</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Surgeon-surveillance n&#x02009;=&#x02009;55 (%)</bold></th><th align="center"><bold>GP-surveillance n&#x02009;=&#x02009;55 (%)</bold></th><th align="center"><bold>Total n&#x02009;=&#x02009;110 (%)</bold></th><th align="center"><bold>p value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Mean age (SD)<hr/></td><td align="center" valign="bottom">66.7 (7.3)<hr/></td><td align="center" valign="bottom">64.0 (8.7)<hr/></td><td align="center" valign="bottom">65.4 (8.1)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Male<hr/></td><td align="center" valign="bottom">32 (58.2)<hr/></td><td align="center" valign="bottom">33 (60.0)<hr/></td><td align="center" valign="bottom">65 (59.1)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Female<hr/></td><td align="center" valign="bottom">23 (41.8)<hr/></td><td align="center" valign="bottom">22 (40.0)<hr/></td><td align="center" valign="bottom">45 (40.9)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Tumour location</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Coecum<hr/></td><td align="center" valign="bottom">13 (23.6)<hr/></td><td align="center" valign="bottom">13 (23.6)<hr/></td><td align="center" valign="bottom">26 (23.6)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Ascendens<hr/></td><td align="center" valign="bottom">9 (16.3)<hr/></td><td align="center" valign="bottom">5 (9.1)<hr/></td><td align="center" valign="bottom">14 (12.7)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Transversum<hr/></td><td align="center" valign="bottom">4 (7.2)<hr/></td><td align="center" valign="bottom">5 (9.1)<hr/></td><td align="center" valign="bottom">9 (8.1)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Decendens<hr/></td><td align="center" valign="bottom">1 (1.8)<hr/></td><td align="center" valign="bottom">4 (1.8)<hr/></td><td align="center" valign="bottom">5 (4.5)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Sigmoid<hr/></td><td align="center" valign="bottom">28 (50.9)<hr/></td><td align="center" valign="bottom">28 (50.9)<hr/></td><td align="center" valign="bottom">56 (50.9)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Type of surgery</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Laparoscopic<hr/></td><td align="center" valign="bottom">14 (25.5)<hr/></td><td align="center" valign="bottom">11 (20.0)<hr/></td><td align="center" valign="bottom">25 (22.7)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Open<hr/></td><td align="center" valign="bottom">41 (74.5)<hr/></td><td align="center" valign="bottom">44 (80.0)<hr/></td><td align="center" valign="bottom">85 (77.3)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Tumour stage</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Dukes A<hr/></td><td align="center" valign="bottom">12 (21.8)<hr/></td><td align="center" valign="bottom">11 (20.0)<hr/></td><td align="center" valign="bottom">24 (21.8)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Dukes B<hr/></td><td align="center" valign="bottom">25 (45.5)<hr/></td><td align="center" valign="bottom">30 (54.5)<hr/></td><td align="center" valign="bottom">55 (50.0)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Dukes C<hr/></td><td align="center" valign="bottom">18 (32.7)<hr/></td><td align="center" valign="bottom">14 (25.5)<hr/></td><td align="center" valign="bottom">32 (29.0)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Total surveillance months<hr/></td><td align="center" valign="bottom">942<hr/></td><td align="center" valign="bottom">942<hr/></td><td align="center" valign="bottom">1884<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Median surveillance (months)<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">NA<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Surveillance tests n</bold><hr/></td><td align="center" valign="bottom">513<hr/></td><td align="center" valign="bottom">592<hr/></td><td align="center" valign="bottom">1105<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Carcinoembryonic antigen CEA (%)<hr/></td><td align="center" valign="bottom">203 (39)<hr/></td><td align="center" valign="bottom">300 (51)<hr/></td><td align="center" valign="bottom">503<hr/></td><td align="center" valign="bottom">&#x0003c;0.001<hr/></td></tr><tr><td align="left" valign="bottom">Chest X-ray (%)<hr/></td><td align="center" valign="bottom">150 (29)<hr/></td><td align="center" valign="bottom">128 (21)<hr/></td><td align="center" valign="bottom">278<hr/></td><td align="center" valign="bottom">0.003<hr/></td></tr><tr><td align="left" valign="bottom">Liver ultrasound (%)<hr/></td><td align="center" valign="bottom">110 (21)<hr/></td><td align="center" valign="bottom">99 (17)<hr/></td><td align="center" valign="bottom">209<hr/></td><td align="center" valign="bottom">0.03<hr/></td></tr><tr><td align="left" valign="bottom">Colonoscopy (%)<hr/></td><td align="center" valign="bottom">50 (9)<hr/></td><td align="center" valign="bottom">65 (11)<hr/></td><td align="center" valign="bottom">115<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left">Consultations n</td><td align="center">508</td><td align="center">678</td><td align="center">1186</td><td align="center">ns</td></tr></tbody></table></table-wrap><sec><title>Serious clinical events and false positive tests</title><p>A total of 48 SCEs were identified; 31 (65%) were initiated by emerging symptoms and 17 (35%) were initiated by test findings. Abdominal pain (n&#x02009;=&#x02009;14, 29%) and blood in the stool (n&#x02009;=&#x02009;10, 20%) were the most common presenting complaints. There were no significant differences between surgeons or GPs in terms of SCE occurrence or the time to diagnosis (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). Overall, 34 patients (30% of all trial patients) experienced a false positive event. The positive predictive value (i.e., the probability of a surveillance-initiated SCE being confirmed as true colon cancer recurrence) was 29% (surgeons 36% vs. GPs 23%).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Serious clinical events with suspicion of cancer recurrence</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Serious clinical event characteristics</bold></th><th align="center"><bold>Surgeon-surveillance</bold></th><th align="center"><bold>GP-surveillance</bold></th><th align="center"><bold>Total</bold></th><th align="center"><bold>p value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Surveillance (months)<hr/></td><td align="center" valign="bottom">942<hr/></td><td align="center" valign="bottom">942<hr/></td><td align="center" valign="bottom">1884<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Interval SCE<hr/></td><td align="center" valign="bottom">12<hr/></td><td align="center" valign="bottom">13<hr/></td><td align="center" valign="bottom">25<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Routine SCE<hr/></td><td align="center" valign="bottom">11<hr/></td><td align="center" valign="bottom">12<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Total SCE<hr/></td><td align="center" valign="bottom">22<hr/></td><td align="center" valign="bottom">26<hr/></td><td align="center" valign="bottom">48<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Symptom initiated SCE</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Abdominal pain (n)<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">11<hr/></td><td align="center" valign="bottom">14<hr/></td><td align="center" valign="bottom">0.05<hr/></td></tr><tr><td align="left" valign="bottom">Blood in stool (n)<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">10<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Anaemia (n)<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Weight loss (n)<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Lymphadenopathy (n)<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Other findings (n)<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Total<hr/></td><td align="center" valign="bottom">13<hr/></td><td align="center" valign="bottom">18<hr/></td><td align="center" valign="bottom">31<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">True cancer recurrence<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Test initiated SCE</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Elevated CEA<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Radiology<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Colonoscopy<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">1<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Total<hr/></td><td align="center" valign="bottom">9<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">17<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">True cancer recurrence<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">False positive tests and symptoms (%)<hr/></td><td align="center" valign="bottom">14 (25%)<hr/></td><td align="center" valign="bottom">20 (36%)<hr/></td><td align="center" valign="bottom">34 (31%)<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Program positive predictive value<hr/></td><td align="center" valign="bottom">0.36<hr/></td><td align="center" valign="bottom">0.23<hr/></td><td align="center" valign="bottom">0.29<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td colspan="4" align="left" valign="bottom"><bold>Diagnostics for potential recurrent cancer</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">CEA (repeated)<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">7<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Chest x-ray<hr/></td><td align="center" valign="bottom">4<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">CEUS<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">6<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Colonoscopy<hr/></td><td align="center" valign="bottom">3<hr/></td><td align="center" valign="bottom">12<hr/></td><td align="center" valign="bottom">15<hr/></td><td align="center" valign="bottom">0.05<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax/abdomen/liver<hr/></td><td align="center" valign="bottom">13<hr/></td><td align="center" valign="bottom">8<hr/></td><td align="center" valign="bottom">21<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">PET<hr/></td><td align="center" valign="bottom">0<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">2<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left" valign="bottom">Consultations<hr/></td><td align="center" valign="bottom">14<hr/></td><td align="center" valign="bottom">23<hr/></td><td align="center" valign="bottom">37<hr/></td><td align="center" valign="bottom">ns<hr/></td></tr><tr><td align="left">Diagnostic work-up days (SD)</td><td align="center">45 (45)</td><td align="center">35 (28)</td><td align="center">39 (35)</td><td align="center">ns</td></tr></tbody></table><table-wrap-foot><p>PPV: positive predictive value, which is the proportion of positive test/clinical findings that are true positives (i.e., true cancer recurrences). ns: not significant.</p></table-wrap-foot></table-wrap></sec><sec><title>Clinical presentation of colon cancer recurrence</title><p>Of the 48 patients with SCEs, 14 (29%) had colon cancer recurrence. Symptoms were the most common initial indication of recurrence (n&#x02009;=&#x02009;7), followed by radiologically detected lesions (n&#x02009;=&#x02009;4) and elevated CEA levels (n&#x02009;=&#x02009;3) (Table&#x000a0;<xref ref-type="table" rid="T4">4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Clinical presentation of colon cancer recurrence</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Case no</bold></th><th align="left"><bold>Gender</bold></th><th align="left"><bold>Presenting problem</bold></th><th align="left"><bold>Routine vs. interval</bold></th><th align="left"><bold>Diagnostic tests</bold></th><th align="left"><bold>Metastatic site</bold></th><th align="left"><bold>Time to diagnosis (days)</bold></th><th align="left"><bold>Metastasis surgery</bold></th><th align="left"><bold>Time to surgery (days)</bold></th></tr></thead><tbody valign="top"><tr><td colspan="9" align="left" valign="bottom"><bold>GP-surveillance</bold><hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">1<hr/></td><td rowspan="2" align="left" valign="bottom">F<hr/></td><td rowspan="2" align="left" valign="bottom">Elevated CEA<hr/></td><td rowspan="2" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CEUS<hr/></td><td rowspan="2" align="left" valign="bottom">Disseminated<hr/></td><td rowspan="2" align="left" valign="bottom">27<hr/></td><td rowspan="2" align="left" valign="bottom">No<hr/></td><td rowspan="2" align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td align="left" valign="bottom">PET CT<hr/></td></tr><tr><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">M<hr/></td><td align="left" valign="bottom">Abdominal pain<hr/></td><td align="left" valign="bottom">Interval<hr/></td><td align="left" valign="bottom">CEUS<hr/></td><td align="left" valign="bottom">Liver<hr/></td><td align="left" valign="bottom">21<hr/></td><td align="left" valign="bottom">No<hr/></td><td align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">3<hr/></td><td rowspan="3" align="left" valign="bottom">M<hr/></td><td rowspan="3" align="left" valign="bottom">Elevated CEA<hr/></td><td rowspan="3" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CEA<hr/></td><td rowspan="3" align="left" valign="bottom">Disseminated<hr/></td><td rowspan="3" align="left" valign="bottom">71<hr/></td><td rowspan="3" align="left" valign="bottom">No<hr/></td><td rowspan="3" align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">4<hr/></td><td rowspan="3" align="left" valign="bottom">M<hr/></td><td rowspan="3" align="left" valign="bottom">Metastatic lesion detected at CEUS<hr/></td><td rowspan="3" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CEUS<hr/></td><td rowspan="3" align="left" valign="bottom">Liver<hr/></td><td rowspan="3" align="left" valign="bottom">4<hr/></td><td rowspan="3" align="left" valign="bottom">Yes<hr/></td><td rowspan="3" align="left" valign="bottom">38<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">5<hr/></td><td rowspan="3" align="left" valign="bottom">F<hr/></td><td rowspan="3" align="left" valign="bottom">Abdominal pain, normal CEA, CT and CEUS, disseminated cancer detected at laparotomy<hr/></td><td rowspan="3" align="left" valign="bottom">Interval<hr/></td><td align="left" valign="bottom">CEUS<hr/></td><td rowspan="3" align="left" valign="bottom">Disseminated<hr/></td><td rowspan="3" align="left" valign="bottom">270<hr/></td><td rowspan="3" align="left" valign="bottom">Yes<hr/></td><td rowspan="3" align="left" valign="bottom">270<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">6<hr/></td><td rowspan="3" align="left" valign="bottom">M<hr/></td><td rowspan="3" align="left" valign="bottom">Abdominal tenderness<hr/></td><td rowspan="3" align="left" valign="bottom">Interval<hr/></td><td align="left" valign="bottom">Anorectoscopy<hr/></td><td rowspan="3" align="left" valign="bottom">Local recurrence<hr/></td><td rowspan="3" align="left" valign="bottom">2<hr/></td><td rowspan="3" align="left" valign="bottom">Yes<hr/></td><td rowspan="3" align="left" valign="bottom">30<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td colspan="9" align="left" valign="bottom"><bold>Surgeon-Surveillance</bold><hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">7<hr/></td><td rowspan="2" align="left" valign="bottom">M<hr/></td><td rowspan="2" align="left" valign="bottom">Metastatic lesion detected chest x-ray<hr/></td><td rowspan="2" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CT thorax<hr/></td><td rowspan="2" align="left" valign="bottom">Lung<hr/></td><td rowspan="2" align="left" valign="bottom">45<hr/></td><td rowspan="2" align="left" valign="bottom">Yes<hr/></td><td rowspan="2" align="left" valign="bottom">62<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">8<hr/></td><td rowspan="3" align="left" valign="bottom">M<hr/></td><td rowspan="3" align="left" valign="bottom">Stoma bleeding<hr/></td><td rowspan="3" align="left" valign="bottom">Interval<hr/></td><td align="left" valign="bottom">Colonoscopy<hr/></td><td rowspan="3" align="left" valign="bottom">Local and lymph node recurrence<hr/></td><td rowspan="3" align="left" valign="bottom">10<hr/></td><td rowspan="3" align="left" valign="bottom">No<hr/></td><td rowspan="3" align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">9<hr/></td><td rowspan="2" align="left" valign="bottom">M<hr/></td><td align="left" valign="bottom">Weight loss<hr/></td><td rowspan="2" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CT Thorax<hr/></td><td rowspan="2" align="left" valign="bottom">Lung<hr/></td><td rowspan="2" align="left" valign="bottom">45<hr/></td><td rowspan="2" align="left" valign="bottom">No<hr/></td><td rowspan="2" align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td align="left" valign="bottom">Night sweating<hr/></td><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">10<hr/></td><td rowspan="2" align="left" valign="bottom">M<hr/></td><td rowspan="2" align="left" valign="bottom">Metastatic lesion detected at chest-x ray<hr/></td><td rowspan="2" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CT Thorax<hr/></td><td rowspan="2" align="left" valign="bottom">Lung<hr/></td><td rowspan="2" align="left" valign="bottom">4<hr/></td><td rowspan="2" align="left" valign="bottom">Yes<hr/></td><td rowspan="2" align="left" valign="bottom">42<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">11<hr/></td><td rowspan="3" align="left" valign="bottom">M<hr/></td><td rowspan="3" align="left" valign="bottom">Metastatic lesion detected on CEUS<hr/></td><td rowspan="3" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">MR liver<hr/></td><td rowspan="3" align="left" valign="bottom">Liver<hr/></td><td rowspan="3" align="left" valign="bottom">3<hr/></td><td rowspan="3" align="left" valign="bottom">Yes<hr/></td><td rowspan="3" align="left" valign="bottom">43<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">12<hr/></td><td rowspan="2" align="left" valign="bottom">F<hr/></td><td rowspan="2" align="left" valign="bottom">Abdominal pain<hr/></td><td rowspan="2" align="left" valign="bottom">Interval<hr/></td><td align="left" valign="bottom">CT abdomen<hr/></td><td rowspan="2" align="left" valign="bottom">Disseminated<hr/></td><td rowspan="2" align="left" valign="bottom">16<hr/></td><td rowspan="2" align="left" valign="bottom">No<hr/></td><td rowspan="2" align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td align="left" valign="bottom">CT thorax<hr/></td></tr><tr><td rowspan="3" align="left" valign="bottom">13<hr/></td><td rowspan="3" align="left" valign="bottom">M<hr/></td><td rowspan="3" align="left" valign="bottom">Elevated CEA<hr/></td><td rowspan="3" align="left" valign="bottom">Routine<hr/></td><td align="left" valign="bottom">CT thorax<hr/></td><td align="left" valign="bottom">Liver<hr/></td><td rowspan="3" align="left" valign="bottom">30<hr/></td><td rowspan="3" align="left" valign="bottom">No<hr/></td><td rowspan="3" align="left" valign="bottom">Inoperable<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td><td rowspan="2" align="left" valign="bottom">Lung<hr/></td></tr><tr><td align="left" valign="bottom">CT liver<hr/></td></tr><tr><td rowspan="2" align="left" valign="bottom">14<hr/></td><td rowspan="2" align="left" valign="bottom">F<hr/></td><td rowspan="2" align="left" valign="bottom">Occult blood in faeces<hr/></td><td rowspan="2" align="left" valign="bottom">Interval<hr/></td><td align="left" valign="bottom">CT thorax<hr/></td><td rowspan="2" align="left" valign="bottom">Liver<hr/></td><td rowspan="2" align="left" valign="bottom">31<hr/></td><td rowspan="2" align="left" valign="bottom">Yes<hr/></td><td rowspan="2" align="left" valign="bottom">35<hr/></td></tr><tr><td align="left" valign="bottom">CT abdomen<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">CEUS</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td><td align="left">&#x000a0;</td></tr></tbody></table></table-wrap></sec><sec><title>Harms and benefits of cancer surveillance</title><p>In this surveillance program, 14 recurrences were detected, seven subsequent surgeries were performed, and four R0 resections of metastases were achieved by surveilling 110 patients over a total of 1884&#x000a0;months. This means that 276 tests and 296 healthcare consultations were needed per R0 resection; the cost per R0 resection was &#x000a3; 103207.</p><p>A 25% increase in successful R0 metastases surgeries decreased the cost per surgery to &#x000a3; 82566 (sensitivity analyses Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). Three patients had asymptomatic but incurable recurrences. Mean time from SCE to confirmation of recurrence was 39&#x000a0;days (standard deviation 35&#x000a0;days). The mean quality of life was equal to that of the general UK population (Table&#x000a0;<xref ref-type="table" rid="T5">5</xref>) [<xref ref-type="bibr" rid="B10">10</xref>].</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>A sensitivity analysis varying the major cost factors.</bold> The base case per R0 resection was set as origo (&#x000a3;103,000). Variance in the number of successful R0 metastases resections has a major impact on overall cost (range &#x000a3; 82,566 to &#x000a3; 123, 847).</p></caption><graphic xlink:href="1472-6963-14-137-1"/></fig><table-wrap position="float" id="T5"><label>Table 5</label><caption><p>Fact box of the side-effects and benefits of CRC surveillance</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variable</bold></th><th align="center"><bold>Surveillance effects</bold></th></tr></thead><tbody valign="top"><tr><td colspan="2" align="left" valign="bottom"><bold>
<italic>Resource use</italic>
</bold><hr/></td></tr><tr><td align="left" valign="bottom">Analysed surveillance months<hr/></td><td align="center" valign="bottom">110 patients for 1884&#x000a0;months<hr/></td></tr><tr><td align="left" valign="bottom">Cost per successful R0 resection (&#x000a3;)<hr/></td><td align="center" valign="bottom">103207<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom"><bold>Screening tests per R0 metastases resection</bold><hr/></td></tr><tr><td align="left" valign="bottom">Carcinoembryonic antigen CEA (n)<hr/></td><td align="center" valign="bottom">125<hr/></td></tr><tr><td align="left" valign="bottom">Chest x-ray (n)<hr/></td><td align="center" valign="bottom">70<hr/></td></tr><tr><td align="left" valign="bottom">Liver ultrasound (n)<hr/></td><td align="center" valign="bottom">52<hr/></td></tr><tr><td align="left" valign="bottom">Colonoscopies (n)<hr/></td><td align="center" valign="bottom">30<hr/></td></tr><tr><td align="left" valign="bottom">Total screening tests (n)<hr/></td><td align="center" valign="bottom">276<hr/></td></tr><tr><td align="left" valign="bottom">Total health care consultations (n)<hr/></td><td align="center" valign="bottom">296<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom"><bold>
<italic>Benefits</italic>
</bold><hr/></td></tr><tr><td align="left" valign="bottom">Number of cancer recurrences detected (n)<hr/></td><td align="center" valign="bottom">14<hr/></td></tr><tr><td align="left" valign="bottom">Probability of R0 metastasis surgery (%)*<hr/></td><td align="center" valign="bottom">57% (4 of 7 metastasis surgeries)<hr/></td></tr><tr><td align="left" valign="bottom"><bold>
<italic>Side effects</italic>
</bold><hr/></td><td align="center" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">False positive events (n)<hr/></td><td align="center" valign="bottom">34 (31%)<hr/></td></tr><tr><td align="left" valign="bottom">Probability of recurrent cancer when diagnostic check up i.e. surveillance positive predictive value<hr/></td><td align="center" valign="bottom">29%<hr/></td></tr><tr><td align="left" valign="bottom"><sup>
<italic>a</italic>
</sup>Mean days to SCE diagnosis (SD)<hr/></td><td align="center" valign="bottom">39 (35)<hr/></td></tr><tr><td align="left" valign="bottom">Asymptomatic but incurable metastases recurrences<hr/></td><td align="center" valign="bottom">3 of 14 recurrences (21%)<hr/></td></tr><tr><td colspan="2" align="left" valign="bottom"><bold>
<italic>Quality of life</italic>
</bold><hr/></td></tr><tr><td align="left" valign="bottom"><sup>a</sup>Mean EQ-5D VAS score (CI)<hr/></td><td align="center" valign="bottom">75.9 (74.5-77.3)<hr/></td></tr><tr><td align="left"><sup>a</sup>Mean EQ-5D Index score (CI)</td><td align="center">0.862 (0.84-0.87)</td></tr></tbody></table><table-wrap-foot><p>*R0 surgery is defined as positive histological resection margins. <sup>a</sup>Reported in a previous publication [<xref ref-type="bibr" rid="B8">8</xref>]. Equals that of the general UK population [<xref ref-type="bibr" rid="B10">10</xref>].</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Summary of findings</title><p>A representative population of patients surgically treated for colon cancer was enrolled in a colon cancer surveillance program based on Norwegian national guidelines, with an expected normal variance of demographic factors and colon cancer severity. The patients were followed for up to two years (i.e., the period during which most cancer recurrences manifest). Thirty percent (34 of 110) of all the surveillance patients experienced false positive tests, and the probability of having a cancer recurrence when a diagnostic check-up was initiated was 29%. Overall, 276 tests were needed to save one patient from recurrent colon cancer, and the total cost per successful surgery for recurrence was &#x000a3; 103207.</p></sec><sec><title>Comparison of existing literature</title><p>The potential negative side effects (physical and psychological) and costs of cancer surveillance strategies have not been well delineated [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. None of the studies included in the previous reviews of colorectal cancer surveillance have provided any specific details of the harms (mortality or morbidity) resulting from investigating or treating recurrences [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>]. However, a potential harm from any secondary prevention program is well recognised to be over-diagnosis and false positive tests [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Some researchers have investigated the psychological effects of colorectal cancer surveillance [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B12">12</xref>,<xref ref-type="bibr" rid="B13">13</xref>]. None of these studies have found deterioration in the patient QoL with surveillance. Nevertheless, in recent meta-analyses, it was shown that anxiety, rather than depression, was a major problem among long-term cancer survivors. It is unknown, however, what impact a cancer surveillance program itself has on anxiety levels [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>The challenge of postoperative cancer surveillance is that a vast majority of patients must undergo a large number of tests without any benefit, or even with some potential harm, to identify a few patients with curable recurrence. The high rate of false positive tests (n&#x02009;=&#x02009;34, 30% of all surveillance patients) in this trial was more than we expected and likely negatively impacts the patient&#x02019;s and family&#x02019;s QoL. False positive and true positive tests in colorectal cancer surveillance have been addressed in previous reviews [<xref ref-type="bibr" rid="B15">15</xref>]. According to Kievit et al., 370 positive surveillance tests (26 true positives, 7%) and 11 surgeries were required to provide one patient with a long-term survival benefit (five years) [<xref ref-type="bibr" rid="B15">15</xref>]. In our survey, 1186 tests were performed during the 1884 person-month surveillance period, which equals 276 tests per successful R0 metastasis surgery. This finding aligned with the results from another Norwegian survey, which reported 270 tests per successful R0 resection [<xref ref-type="bibr" rid="B16">16</xref>]. The estimated cost of &#x000a3; 103207 per successful R0 metastases resection is higher than reported by other authors. K&#x000f8;rner et al. reported an estimated cost per R0 resection of &#x000a3; 15278 (US $ 25289),</p><p>Identification of asymptomatic but incurable recurrent disease through surveillance testing raises ethical and quality of life considerations [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. In our study, three patients (21%, Table&#x000a0;<xref ref-type="table" rid="T4">4</xref>) had asymptomatic but incurable colon cancer recurrence. These figures are somewhat higher than those in a previous study reporting 9% asymptomatic but incurable disease detected in a surveillance program [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>The imperfect nature of specific surveillance tests themselves (i.e., test sensitivity and specificity) can contribute to the potential harms of surveillance. National surveillance programs are often based on serial CEA measurements, and this biomarker has several pitfalls and shortcomings. A recent study showed that the diagnostic accuracy of serial CEA measurements is low and is impacted by the cut-off value used [<xref ref-type="bibr" rid="B18">18</xref>]. Similarly, radiological tests have varying sensitivity and specificity, the latter of which impacts the rate of false positive tests. For example, the rate of false positive tests in CT chest scans has been reported to be as high as 30-50%; as a result, this test is not recommended by some physicians for post-treatment surveillance purposes [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>Studies of secondary prevention practices around other cancer types have explored potential harmful effects of these programs. In a systematic review addressing screening for lung cancer using thoracic CT scans, most of the detected lung nodules (&#x0003e; 90%) were benign, and invasive nonsurgical procedures in patients with benign lesions were common [<xref ref-type="bibr" rid="B20">20</xref>]. Forty-six percent of patients reported psychological distress while awaiting the confirmation of a potential cancer diagnosis [<xref ref-type="bibr" rid="B21">21</xref>]. Thus, the potential harms of a preventive program must be carefully weighed against any benefits [<xref ref-type="bibr" rid="B20">20</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. In the case of colonoscopic colorectal cancer surveillance, the potential harms of the procedure (including significant discomfort, bleeding, and perforation) coupled with the low rate of intraluminal cancer recurrence, have led some to debate whether colonoscopy should be routinely included in surveillance programs [<xref ref-type="bibr" rid="B23">23</xref>].</p></sec><sec><title>Strengths and limitations</title><p>This study has some strength. It represents the first trial to analyse the potential side effects of colon cancer surveillance, an area of considerable uncertainty. Jeffery and Hider outlined this uncertainty around side effects of colorectal cancer surveillance in their 2007 Cochrane review [<xref ref-type="bibr" rid="B3">3</xref>]. This study has limitations. The trial was designed to assess whether general practice surveillance affected patient-specific QoL and cost-effectiveness compared to surgeon-led surveillance [<xref ref-type="bibr" rid="B9">9</xref>]. A trial assessing survival would require a larger sample size and a longer surveillance time. We acknowledge that this choice of a follow-up period might have impacted the observed frequency of SCE and thus of recurrence. Thirteen percent (n&#x02009;=&#x02009;14) of trial patients had colon cancer recurrence; this low recurrence rate was most likely related, at least partly, to the short follow-up duration (median 17&#x000a0;months). Therefore, our calculation of the cost per successful R0 recurrence surgery might represent an overestimate. To address this uncertainty, we performed a sensitivity analysis in which we estimated the cost per R0 resection if a 25% increase in successful resections was observed (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). However, in our opinion, the analysed time period gives a realistic overview of the magnitude and rate of side effects in a colon cancer surveillance program.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Information on a range of outcomes should be available to fully assess the net benefit or harm of colon cancer surveillance. Any survival benefit of the surveillance must be balanced against the potential harms inherent to ensure that surveillance programs are acceptable. Providers are best positioned to inform patients and their families of these benefits and potential harms. The nature of postoperative cancer surveillance is that a vast majority of patients (96% in the present study) must undergo a large number of tests without any benefit, or even with some harm to themselves and their family, to identify a few patients with curable recurrence. Patients with asymptomatic but incurable disease (21% of all recurrences in the present study) likely represent the most controversial group and raise ethical and quality of life considerations [<xref ref-type="bibr" rid="B16">16</xref>]. The reported cost of &#x000a3; 103207 per R0 resection of recurrent disease is significantly higher than that reported by others [<xref ref-type="bibr" rid="B16">16</xref>].</p><p>In conclusion, due to the high rate of false positive tests and low positive predictive value of the surveillance program examined, we feel that a more tailored surveillance approach based on recurrence risk and likely recurrence pattern is needed in future CRC surveillance programs. Such an approach has the potential to reduce costs and the number of false positive tests, while improving positive predictive value. There is nothing in the current evidence base suggesting that such an approach will compromise the potential survival benefit of CRC surveillance. In addition, further research is needed regarding the potential harms of colorectal cancer surveillance, including quality of life impacts due to false positive surveillance tests and to early diagnosis of incurable recurrence. The estimated cost of surveillance is considerable, and whether the identified costs are acceptable when comparing the benefits and harms is a matter of discussion not only among policy and decision makers, but also among providers, patients, and families.</p></sec><sec><title>Competing interests</title><p>We declare that we have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>KMA and ROL conceived and designed the research idea and were responsible for the overall administration and direction of the study, the analysis and the data interpretation. KMA performed the statistical analyses. KMA performed the economic analysis with assistance from JN, who contributed to the design, data analysis and interpretation of the findings. KMA wrote the first draft. JR provided substantive revisions and interpretation of results. All of the authors read and approved the final manuscript. KMA had full access to all the data in the study and had final responsibility for the decision to submit the manuscript for publication.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1472-6963/14/137/prepub">http://www.biomedcentral.com/1472-6963/14/137/prepub</ext-link></p></sec></body><back><sec><title>Acknowledgements</title><p>Funding was obtained from Northern Norway Regional Health Authority Trust. Johnie Rose was supported for this work in part by a National Cancer Institute Program Grant (5P30 CA043703-21) and by an American Cancer Society Mentored Research Scholar Grant 124673-MRSG-13-315-01-CPHPS. We thank Barthold Vonen, Torunn Nestvold, Caroline Sagatun, Ranveig Aspevik, Stefan Dehof, Henriette Fagertun and Unni Ringberg for comments on the initial study protocol, identifying trial participants and extracting EMR data. We thank Trine Hansen at the Norwegian Centre for Integrated Care and Telemedicine for administrative support and maintaining the research database. We thank professor Roar Johnsen, Department of Public Health and General Practice, Norwegian University of Science and Technology, for assistance in protocol writing and designing the trial. We thank Frank Hauboff, Surgical Outpatient Clinic, University Hospital of North Norway, for clinical assistance and for identifying potential trial participants.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Larsen</surname><given-names>I</given-names></name><article-title>Cancer registry of Norway</article-title><source>Cancer Norway</source><year>2011</year><volume>14</volume><fpage>1</fpage><lpage>90</lpage><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.kreftregisteret.no/no/Generelt/Publikasjoner/Cancer-in-Norway/Cancer-in-Norway-2011/">http://www.kreftregisteret.no/no/Generelt/Publikasjoner/Cancer-in-Norway/Cancer-in-Norway-2011/</ext-link></comment></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Tjandra</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>MKY</given-names></name><article-title>Follow-up after curative resection of colorectal cancer: a meta-analysis</article-title><source>Dis Colon Rectum</source><year>2007</year><volume>14</volume><fpage>1783</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1007/s10350-007-9030-5</pub-id><pub-id pub-id-type="pmid">17874269</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Jeffery</surname><given-names>M</given-names></name><name><surname>Hickey</surname><given-names>BE</given-names></name><name><surname>Hider</surname><given-names>PN</given-names></name><article-title>Follow-up strategies for patients treated for non-metastatic colorectal cancer</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>14</volume><fpage>1</fpage><lpage>25</lpage></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>KG</given-names></name><article-title>Prevention. How much harm? How much benefit? 1. Influence of reporting methods on perception of benefits</article-title><source>Can Med Assoc J</source><year>1996</year><volume>14</volume><fpage>1493</fpage><pub-id pub-id-type="pmid">8624999</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>KG</given-names></name><article-title>Prevention. How much harm? How much benefit? 2. Ten potential pitfalls in determining the clinical significance of benefits</article-title><source>Can Med Assoc J</source><year>1996</year><volume>14</volume><fpage>1837</fpage><pub-id pub-id-type="pmid">8653643</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Marshall</surname><given-names>KG</given-names></name><article-title>Prevention. How much harm? How much benefit? 3. Physical, psychological and social harm</article-title><source>Can Med Assoc J</source><year>1996</year><volume>14</volume><fpage>169</fpage><pub-id pub-id-type="pmid">8800074</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><collab>Independent UK Panel on Breast Cancer Screening</collab><article-title>The benefits and harms of breast cancer screening: an independent review</article-title><source>Lancet</source><year>2012</year><volume>14</volume><fpage>1778</fpage><lpage>1786</lpage><pub-id pub-id-type="pmid">23117178</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Augestad</surname><given-names>KM</given-names></name><name><surname>Norum</surname><given-names>J</given-names></name><name><surname>Dehof</surname><given-names>S</given-names></name><name><surname>Aspevik</surname><given-names>R</given-names></name><name><surname>Ringberg</surname><given-names>U</given-names></name><name><surname>Nestvold</surname><given-names>T</given-names></name><name><surname>Vonen</surname><given-names>B</given-names></name><name><surname>Skr&#x000f8;vseth</surname><given-names>SO</given-names></name><name><surname>Lindsetmo</surname><given-names>R-O</given-names></name><article-title>Cost-effectiveness and quality of life in surgeon versus general practitioner-organised colon cancer surveillance: a randomised controlled trial</article-title><source>BMJ Open</source><year>2013</year><volume>14</volume><issue>4</issue><comment>doi:10.1136/bmjopen-2012-002391</comment></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Augestad</surname><given-names>KM</given-names></name><name><surname>Vonen</surname><given-names>B</given-names></name><name><surname>Aspevik</surname><given-names>R</given-names></name><name><surname>Nestvold</surname><given-names>T</given-names></name><name><surname>Ringberg</surname><given-names>U</given-names></name><name><surname>Johnsen</surname><given-names>R</given-names></name><name><surname>Norum</surname><given-names>J</given-names></name><name><surname>Lindsetmo</surname><given-names>R-O</given-names></name><article-title>Should the surgeon or the general practitioner (GP) follow up patients after surgery for colon cancer? A randomized controlled trial protocol focusing on quality of life, cost-effectiveness and serious clinical events</article-title><source>BMC Health Serv Res</source><year>2008</year><volume>14</volume><fpage>137</fpage><pub-id pub-id-type="doi">10.1186/1472-6963-8-137</pub-id><pub-id pub-id-type="pmid">18578856</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Roset</surname><given-names>M</given-names></name><article-title>Sample size cacluations using EQ-5D</article-title><source>Qual Life Res</source><year>1999</year><volume>14</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">10457733</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Njor</surname><given-names>SH</given-names></name><name><surname>Olsen</surname><given-names>AH</given-names></name><name><surname>Blichert-Toft</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>W</given-names></name><name><surname>Vejborg</surname><given-names>I</given-names></name><name><surname>Lynge</surname><given-names>E</given-names></name><article-title>Overdiagnosis in screening mammography in Denmark: population based cohort study</article-title><source>BMJ</source><year>2013</year><volume>14</volume><fpage>f1064</fpage><lpage>f1064</lpage><pub-id pub-id-type="doi">10.1136/bmj.f1064</pub-id><pub-id pub-id-type="pmid">23444414</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Wattchow</surname><given-names>DA</given-names></name><name><surname>Weller</surname><given-names>DP</given-names></name><name><surname>Esterman</surname><given-names>A</given-names></name><name><surname>Pilotto</surname><given-names>LS</given-names></name><name><surname>McGorm</surname><given-names>K</given-names></name><name><surname>Hammett</surname><given-names>Z</given-names></name><name><surname>Platell</surname><given-names>C</given-names></name><name><surname>Silagy</surname><given-names>C</given-names></name><article-title>General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial</article-title><source>Br J Cancer</source><year>2006</year><volume>14</volume><fpage>1116</fpage><lpage>1121</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6603052</pub-id><pub-id pub-id-type="pmid">16622437</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Gall</surname><given-names>CA</given-names></name><name><surname>Weller</surname><given-names>D</given-names></name><name><surname>Esterman</surname><given-names>A</given-names></name><name><surname>Pilotto</surname><given-names>L</given-names></name><name><surname>McGorm</surname><given-names>K</given-names></name><name><surname>Hammett</surname><given-names>Z</given-names></name><name><surname>Wattchow</surname><given-names>D</given-names></name><article-title>Patient satisfaction and health-related quality of life after treatment for colon cancer</article-title><source>Dis Colon Rectum</source><year>2007</year><volume>14</volume><fpage>801</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1007/s10350-006-0815-8</pub-id><pub-id pub-id-type="pmid">17285234</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Mitchell</surname><given-names>A</given-names></name><name><surname>Ferguson</surname><given-names>DW</given-names></name><name><surname>Gill</surname><given-names>J</given-names></name><article-title>Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis</article-title><source>Lancet Oncol</source><year>2013</year><volume>14</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(12)70595-8</pub-id><pub-id pub-id-type="pmid">23276361</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Kievit</surname><given-names>J</given-names></name><article-title>Follow-up of patients with colorectal cancer: numbers needed to test and treat</article-title><source>Eur J Cancer</source><year>2002</year><volume>14</volume><fpage>986</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(02)00061-8</pub-id><pub-id pub-id-type="pmid">11978524</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>K&#x000f6;rner</surname><given-names>H</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>K</given-names></name><name><surname>Stokkeland</surname><given-names>PJ</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>JA</given-names></name><article-title>Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance</article-title><source>J Gastrointest Surg</source><year>2005</year><volume>14</volume><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.gassur.2004.09.023</pub-id><pub-id pub-id-type="pmid">15749591</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Loprinzi</surname><given-names>C</given-names></name><name><surname>Hayes</surname><given-names>DD</given-names></name><name><surname>Smith</surname><given-names>TT</given-names></name><article-title>Doc, shouldn&#x02019;t we be getting some tests?</article-title><source>J Clin Oncol</source><year>2003</year><volume>14</volume><fpage>108s</fpage><lpage>111s</lpage><pub-id pub-id-type="doi">10.1200/JCO.2003.01.190</pub-id><pub-id pub-id-type="pmid">12743213</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>K&#x000f6;rner</surname><given-names>H</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>K</given-names></name><name><surname>Stokkeland</surname><given-names>PJ</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>JA</given-names></name><article-title>Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis</article-title><source>Ann Surg Oncol</source><year>2006</year><volume>14</volume><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">17103264</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Grossmann</surname><given-names>I</given-names></name><name><surname>Avenarius</surname><given-names>JKA</given-names></name><name><surname>Mastboom</surname><given-names>WJB</given-names></name><name><surname>Klaase</surname><given-names>JM</given-names></name><article-title>Preoperative staging with chest ct in patients with colorectal carcinoma: not as a routine procedure</article-title><source>Ann Surg Oncol</source><year>2010</year><volume>14</volume><fpage>2045</fpage><lpage>2050</lpage><pub-id pub-id-type="doi">10.1245/s10434-010-0962-y</pub-id><pub-id pub-id-type="pmid">20151212</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Mirkin</surname><given-names>JN</given-names></name><article-title>Benefits and harms of CT screening for lung cancer: a systematic review</article-title><source>JAMA: J Am Med Assoc</source><year>2012</year><volume>14</volume><fpage>2418</fpage><lpage>2429</lpage><pub-id pub-id-type="doi">10.1001/jama.2012.5521</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>van den Bergh</surname><given-names>K</given-names></name><name><surname>Essink-Bot</surname><given-names>M</given-names></name><name><surname>Borsboom</surname><given-names>G</given-names></name><name><surname>Scholten</surname><given-names>E</given-names></name><name><surname>van Klaveren</surname><given-names>R</given-names></name><name><surname>de Koning</surname><given-names>H</given-names></name><article-title>Long-term effects of lung cancer computed tomography screening on health-related quality of life: the NELSON trial</article-title><source>Eur Respir J</source><year>2011</year><volume>14</volume><fpage>154</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1183/09031936.00123410</pub-id><pub-id pub-id-type="pmid">21148229</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Brewer</surname><given-names>NT</given-names></name><name><surname>Salz</surname><given-names>T</given-names></name><article-title>Systematic review: the long-term effects of false-positive mammograms</article-title><source>Ann Intern Med</source><year>2007</year><volume>14</volume><fpage>502</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-146-7-200704030-00006</pub-id><pub-id pub-id-type="pmid">17404352</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>S&#x000f8;reide</surname><given-names>K</given-names></name><article-title>Endoscopic surveillance after curative surgery for sporadic colorectal cancer: patient-tailored, tumor-targeted or biology-driven?</article-title><source>Scand J Gastroenterol</source><year>2010</year><volume>14</volume><fpage>1255</fpage><lpage>1261</lpage><pub-id pub-id-type="pmid">20553114</pub-id></mixed-citation></ref></ref-list></back></article>